{"title":"对GLP-1试验的回顾发现自杀风险发生率低","authors":"","doi":"10.1002/pu.31321","DOIUrl":null,"url":null,"abstract":"<p>A systematic review and meta-analysis comprising 27 trials comparing glucagon-like peptide 1 (GLP-1) receptor agonists and placebo in patients with type 2 diabetes or obesity found no significantly increased risk of suicidal behavior in conjunction with the popular medications. The incidence of suicide and self-harm was very low in both the GLP-1 and placebo groups. Results of the review were published online March 19, 2025, in <i>JAMA Psychiatry</i>.</p>","PeriodicalId":22275,"journal":{"name":"The Brown University Psychopharmacology Update","volume":"36 7","pages":"1-6"},"PeriodicalIF":0.0000,"publicationDate":"2025-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Review of GLP-1 trials finds low incidence of suicide risk\",\"authors\":\"\",\"doi\":\"10.1002/pu.31321\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>A systematic review and meta-analysis comprising 27 trials comparing glucagon-like peptide 1 (GLP-1) receptor agonists and placebo in patients with type 2 diabetes or obesity found no significantly increased risk of suicidal behavior in conjunction with the popular medications. The incidence of suicide and self-harm was very low in both the GLP-1 and placebo groups. Results of the review were published online March 19, 2025, in <i>JAMA Psychiatry</i>.</p>\",\"PeriodicalId\":22275,\"journal\":{\"name\":\"The Brown University Psychopharmacology Update\",\"volume\":\"36 7\",\"pages\":\"1-6\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-06-02\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The Brown University Psychopharmacology Update\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/pu.31321\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Brown University Psychopharmacology Update","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/pu.31321","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Review of GLP-1 trials finds low incidence of suicide risk
A systematic review and meta-analysis comprising 27 trials comparing glucagon-like peptide 1 (GLP-1) receptor agonists and placebo in patients with type 2 diabetes or obesity found no significantly increased risk of suicidal behavior in conjunction with the popular medications. The incidence of suicide and self-harm was very low in both the GLP-1 and placebo groups. Results of the review were published online March 19, 2025, in JAMA Psychiatry.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
